Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
| ▸ | ARHGDIA | P52565 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019763 | 1.00 | ROCK2 (0.55) | ROCK2ROCK1ARHGDIAKCNH2OPRK1 | |
| SCHEMBL3527134 | 0.85 | ROCK2 (0.59) | ROCK2ROCK1ARHGDIAKCNH2OPRK1 | |
| SCHEMBL4014383 | 0.81 | MEN1 (0.56) | ROCK2ROCK1ARHGDIAKCNH2OPRK1 | |
| SCHEMBL18741418 | 0.79 | ROCK2 (0.67) | ROCK2ROCK1 | |
| SCHEMBL18741420 | 0.79 | ROCK2 (0.67) | ROCK2ROCK1 | |
| SCHEMBL6017233 | 0.79 | MEN1 (0.54) | ROCK2ROCK1ARHGDIAKCNH2OPRK1 | |
| SCHEMBL5821200 | 0.77 | MEN1 (0.38) | LTA4HALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5958407 | 0.73 | AOC1 (0.54) | ROCK2ROCK1MEN1KMT2AMAPT | |
| SCHEMBL29539060 | 0.73 | AOC1 (0.54) | ROCK2ROCK1MEN1KMT2AMAPT | |
| SCHEMBL1976077 | 0.71 | ROCK2 (0.68) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579471-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070185157-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-7217721-B2 | Tropane derivatives useful in therapy | PFIZER, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1492789-B1 | TROPANE DERIVATIVES AS CCR5 MODULATORS | PFIZER LTD (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050107424-A1 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6855724-B2 | Tropane derivatives useful in therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040014742-A1 | Antiinflammatory agents; viricides | PFIZER INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014742-A1 | Antiinflammatory agents; viricides | CCR5, CXCR1, CCR1 | ROCK2 1134/4885ROCK1 466/4885ARHGDIA 786/4885 |
| US-20050107424-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | ROCK2 1696/4885ROCK1 1402/4885ARHGDIA 964/4885 |
| US-20070185157-A1 | Tropane derivatives useful in therapy | CCR5, CXCR4, CX3CR1 | ROCK2 1696/4885ROCK1 1402/4885ARHGDIA 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.